Related Experiment Video

Updated: Mar 18, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.6K

Apatinib for the treatment of gastric cancer

Giandomenico Roviello1,2, Andrea Ravelli3, Anna Ida Fiaschi4

  • 1a Department of Molecular and Translational Medicine , University of Brescia , Brescia , Italy.

Expert Review of Gastroenterology & Hepatology
|July 5, 2016
PubMed
Abstract

Insights

Apatinib shows promise as a targeted therapy for advanced gastric cancer by inhibiting VEGFR2. Further research is needed to identify predictive biomarkers for patient selection.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Apatinib is a novel small-molecule inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR2).
  • Preclinical studies indicate significant anti-cancer effects of apatinib in gastric cancer models.

Purpose of the Study:

  • To review the mechanism of action, pharmacokinetics, and clinical efficacy of apatinib in advanced/metastatic gastric cancer.
  • To highlight the current limitations regarding predictive biomarker data for apatinib in this patient population.

Main Methods:

  • Review of Phase II and Phase III clinical trial data for apatinib in metastatic/advanced gastric cancer.
  • Analysis of preclinical in vitro and in vivo study findings.

Main Results:

  • Apatinib demonstrates encouraging anti-cancer activity in gastric cancer.
  • Clinical evaluations in Phase II and III studies support its use in advanced/metastatic settings.

Conclusions:

  • Apatinib is a potential therapeutic option for advanced/metastatic gastric cancer.
  • The lack of definitive predictive biomarkers remains a significant challenge for personalized treatment strategies.
Keywords:
Gastric cancerVEGFR2angiogenesisapatinibchemotherapy

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
723
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K